This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eto, K. Articles by Sato, T. Search for Related Content PubMed PubMed Citation Articles by Eto, K. Articles by Sato, T. Related Collections Acute coronary syndromes Coagulation and fibronolysis Platelets

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:877-882.)
© 1999 American Heart Association, Inc.

Original Contributions

AJvW-2, an Anti-vWF Monoclonal Antibody, Inhibits Enhanced Platelet Aggregation Induced by High Shear Stress in Platelet-Rich Plasma From Patients With Acute Coronary Syndromes

Koji Eto; Takaaki Isshiki; Hiroshi Yamamoto; Satoshi Takeshita; Masahiko Ochiai; Naoyuki Yokoyama; Ryota Yoshimoto; Yasuo Ikeda; Tomohide Sato

From the Department of Medicine (Cardiology), Teikyo University School of Medicine, Tokyo (K.E., T.I., S.T., M.O., N.Y., T.S.); the Central Research Laboratories, Ajinomoto Co, Inc, Yokohama (H.Y., R.Y.); and the Department of Medicine (Hematology), Keio University School of Medicine, Tokyo (Y.I.), Japan.

Correspondence to Koji Eto, MD, Department of Medicine (Cardiology), Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173, Japan. E-mail keto{at}med.teikyo-u.ac.jp

Abstract—The platelet aggregation that is dependent on von Willebrand factor (vWF) is important in the thrombogenesis that occurs under conditions of high shear stress, eg, during acute coronary syndromes (ACSs). A monoclonal antibody, AJvW-2, directed against the A1 domain of human vWF specifically blocks the interaction between plasma vWF and platelet glycoprotein (GP) Ib. To evaluate the association between the vWF-GPIb interaction and the enhanced shear-induced platelet aggregation (SIPA) observed in ACSs, we tested the effect of this antibody on platelet aggregation. Platelet-rich plasma was prepared from the citrated blood of 12 patients with unstable angina (UAP) and 20 patients with acute myocardial infarction (AMI) who were admitted within 3 hours of the onset of cardiac symptoms and from 18 controls. We observed the following: (1) 1.7-fold higher plasma levels of vWF and ristocetin cofactor activity in UAP patients and (2) 2.8-fold higher levels in the AMI group than in controls. Using a cone-and-plate viscometer, we measured the mean value of SIPA under high-shear conditions (108 dyne/cm²) and found them to be 1.3-fold higher in the UAP group and 2.0-fold higher in the AMI group than in controls. The high SIPA in all groups was completely inhibited by 10 µg/mL AJvW-2. Under low-shear conditions (12 dyne/cm²), platelet aggregation was increased only in the AMI group, but this was unaffected by AJvW-2. We observed a significant correlation in both ACS groups between high SIPA and the plasma vWF level or vWF larger multimers. These findings suggest that the vWF-GPIb interaction is important in coronary occlusion and that inhibition of this interaction (with the use of AJvW-2) may prevent further events in the coronary arteries.

Key Words: platelet aggregation • shear stress • glycoprotein Ib • von Willebrand factor • acute coronary syndromes

This article has been cited by other articles:

				O. Inoue, K. Suzuki-Inoue, and Y. Ozaki Redundant Mechanism of Platelet Adhesion to Laminin and Collagen under Flow: INVOLVEMENT OF VON WILLEBRAND FACTOR AND GLYCOPROTEIN Ib-IX-V J. Biol. Chem., June 13, 2008; 283(24): 16279 - 16282. [Abstract] [Full Text] [PDF]

				A. O. Spiel, J. C. Gilbert, and B. Jilma Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes Circulation, March 18, 2008; 117(11): 1449 - 1459. [Abstract] [Full Text] [PDF]

				N. Inami, S. Nomura, Y. Kimura, K. Yamada, H. Nakamori, N. Takahashi, S. Fukuhara, and T. Iwasaka Evaluation of Platelet and Leukocyte Functions in Effort Angina Patients Using High Shear Conditions in Small-Sized Collagen Bead Columns Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 428 - 431. [Abstract] [PDF]

				S. Anwaruddin, A. T. Askari, and E. J. Topol Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine J. Am. Coll. Cardiol., January 23, 2007; 49(3): 279 - 289. [Abstract] [Full Text] [PDF]

				A. Bonnefoy, H. Yamamoto, C. Thys, M. Kito, J. Vermylen, and M. F. Hoylaerts Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha Blood, February 15, 2003; 101(4): 1375 - 1383. [Abstract] [Full Text] [PDF]

				S. Kageyama, H. Yamamoto, H. Nakazawa, J. Matsushita, T. Kouyama, A. Gonsho, Y. Ikeda, and R. Yoshimoto Pharmacokinetics and Pharmacodynamics of AJW200, a Humanized Monoclonal Antibody to von Willebrand Factor, in Monkeys Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 187 - 192. [Abstract] [Full Text] [PDF]